XML 28 R17.htm IDEA: XBRL DOCUMENT

OTHER ASSETS

3 Months Ended

Mar. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

NOTE 11 – OTHER ASSETS

On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:

SCHEDULE OF WARRANTS ASSUMPTIONS

	March 31, 2025		March 31, 2024
Price at valuation	$	-	$	0.02
Exercise price	$	-	$	0.19
Risk free interest		-		4.20	%
Expected term (in years)		-		6
Volatility		-		125.4	%

The Company considers this to be Level 3 inputs and is valued at each reporting period. As of September 12, 2024, the company terminated the licensing agreement with Sanuwave and recognized $3,000 in gain/loss of termination of investment, offset by change in fair value through the date of termination of $1,000. The fair value of these warrants for the three months ended March 31, 2025, and 2024 was $0 and $1,000, respectively. There was a net $0 and $1,000 change in fair value during the three months ended March 31, 2025, and 2024, respectively.

Financial Liabilities Measured at Fair Value on a Recurring Basis

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

●	Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

●	Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

●	Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 3 during the three months ended March 31, 2025, and 2024.

The following table presents changes in Level 3 asset and liability measured at fair value for the three months ended March 31, 2025 and 2024:

	Asset
Balance – December 31, 2023	$	1,000
Fair value adjustments – Sanuwave warrants		1,000
Balance – March 31, 2024	$	2,000

Balance – December 31, 2024		-
Fair value adjustments – Sanuwave warrants		-
Balance – March 31, 2025	$	-

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:

Fair Value Measurements as of March 31, 2025

Level I

Level II

Level III

Total

Asset:

Other assets

	Level I		Level II		Level III		Total
	Fair Value Measurements as of March 31, 2024
	Level I		Level II		Level III		Total
Asset:
Other assets	$	-	$	-	$	1,000	$	1,000